Get the Stockscreener App
3.35
0.60%
0.02
After Hours:
3.35
Olema Pharmaceuticals Inc stock is traded at $3.35, with a volume of 1.40M.
It is up +0.60% in the last 24 hours and down -20.43% over the past month.
See More
Previous Close:
$3.33
Open:
$3.25
24h Volume:
1.40M
Relative Volume:
1.34
Market Cap:
$228.92M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-1.5581
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-20.24%
1M Performance:
-20.43%
6M Performance:
-71.02%
1Y Performance:
-69.77%
1-Day Range:
$3.15
$3.43
1-Week Range:
$3.15
$4.255
52-Week Range:
$3.15
$16.62
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
3.35 | 228.92M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
HighTower Advisors LLC Makes New $510,000 Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
10,352 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Bought by Teacher Retirement System of Texas - Defense World
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Olema Expands Team: 5 Key Hires Receive Equity Compensation Package - Stock Titan
Top Premarket Decliners - MarketScreener
Insiders Could Have Profited By Holding onto Olema Pharmaceuticals Shares Despite 13% Drop - simplywall.st
Olema Pharmaceuticals stock hits 52-week low at $3.86 By Investing.com - Investing.com South Africa
Olema Pharmaceuticals stock hits 52-week low at $3.86 - Investing.com
HighTower Advisors LLC Takes $510,000 Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
JPMorgan Chase & Co. Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $28.00 - MarketBeat
Pier Capital LLC Acquires New Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Bank of New York Mellon Corp Trims Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology to Present Preclinical Data for OP-3136, a - GlobeNewswire
Victory Capital Management Inc. Cuts Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Cancer Breakthrough: New Drug Shows Powerful Anti-Tumor Effects in Prostate, Ovarian, Lung Cancers - Stock Titan
What is Lifesci Capital's Estimate for OLMA FY2025 Earnings? - MarketBeat
HC Wainwright Has Positive Forecast for OLMA Q1 Earnings - MarketBeat
What is HC Wainwright's Forecast for OLMA FY2029 Earnings? - MarketBeat
Olema Pharmaceuticals' (OLMA) "Outperform" Rating Reiterated at Oppenheimer - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Victory Capital Management Inc. Sells 758,412 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
FY2025 EPS Estimate for Olema Pharmaceuticals Cut by Analyst - Defense World
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - Defense World
Olema Pharmaceuticals Inc (OLMA) Shares Rise Despite Market Challenges - The News Heater
Olema Oncology Reports 2024 Financial and Clinical Progress - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Earns “Outperform” Rating from Oppenheimer - Defense World
What is HC Wainwright’s Forecast for OLMA FY2029 Earnings? - Defense World
HC Wainwright Reiterates “Buy” Rating for Olema Pharmaceuticals (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals stock hits 52-week low at $3.94 By Investing.com - Investing.com Australia
Olema Pharmaceuticals stock hits 52-week low at $3.94 - Investing.com India
Olema Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Olema Oncology price target lowered to $25 from $30 at Oppenheimer - TipRanks
Olema Pharmaceuticals Q4 Net Loss Widens -March 18, 2025 at 04:37 pm EDT - Marketscreener.com
Olema Pharmaceuticals Inc Reports Q4 2024 EPS of -$0.63 and Net - GuruFocus.com
Olema Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Olema Pharmaceuticals Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):